drugset / Trial / NCT05691361
Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients
Phase 1/2
Active not recruiting
53 enrolled
ADARx Pharmaceuticals, Inc.
Avance Clinical Pty Ltd. · collab
RandomizedSequentialDouble-blindTreatment
Summary
The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).
Timeline
- Start
- 2022-12-14
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |